New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
15:26 EDTGMCR, NYCB, DELL, CELG, EXPRStocks with expanding option implied volatility; EXPR DELL GMCR CELG NYCB
News For EXPR;DELL;GMCR;CELG;NYCB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 30, 2015
09:05 EDTCELGCelgene receives orphan status for lymphoma treatment
The FDA granted Celgene for its treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, Revlimid.
09:04 EDTCELGCelgene receives orphan status for lymphoma treatment
07:44 EDTCELGAcceleron, Celgene select Luspatercept to advance to Phase 3
Acceleron Pharma (XLRN) announced that Acceleron and its collaboration partner, Celgene Corporation (CELG), plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015. The companies will continue to develop sotatercept for patients with chronic kidney disease. Preliminary data from the ongoing phase 2 clinical trial of luspatercept in patients with lower risk MDS will be presented by Uwe Platzbecker, M.D., University Hospital in Dresden, Germany, in the oral session “Best of Clinical Trials II” at the MDS Foundation 13th International Symposium on Myelodysplastic Syndromes on Saturday May 2, 2015, at 10:30 AM at the Washington Marriott Wardman Park Hotel in Washington, D.C.
07:32 EDTCELGCelgene reaffirms FY15 adjusted EPs view $4.60-$4.75, consensus $4.81
Reaffirms total net product sales $9B-$9.5B, consensus $9.32B. REVLIMID® net sales are expected to be in the range of $5,600 million to $5,700 million ABRAXANE® net sales are expected to be in the range of $1,000 million to $1,250 million
07:32 EDTCELGCelgene reports Q1 adjusted EPS $1.07, consensus $1.06
Subscribe for More Information
April 29, 2015
15:00 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
07:16 EDTNYCBNew York Community Bancorp reports Q1 cash EPS 29c, consensus 26c
Subscribe for More Information
07:16 EDTCELGAgios Pharmaceuticals plans to advance AG-881 to clinical development
Subscribe for More Information
April 28, 2015
15:07 EDTNYCBNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include MasterCard (MA), consensus 80c... Time Warner (TWX), consensus $1.09... Mondelez (MDLZ), consensus 38c... NextEra Energy (NEE), consensus $1.27... General Dynamics (GD), consensus $1.95... Lumber Liquidators (LL), consensus 16c... Southern Co (SO), consensus 58c... Anthem (ANTM), consensus $2.66... Praxair (PX), consensus $1.44... Norfolk Southern (NSC), consensus $1.00... Eaton (ETN), consensus 98c... Thomson Reuters (TRI), consensus 45c... Franklin Resources (BEN), consensus 86c... Northrop Grumman (NOC), consensus $2.27... Hilton Worldwide (HLT), consensus 12c... Exelon (EXC), consensus 69c... Humana (HUM), consensus $2.56... International Paper (IP), consensus 80c... Hess (HES), consensus ($1.05)... Level 3 Communications (LVLT), consensus 33c... Starwood Hotels & Resorts (HOT), consensus 57c... Ametek (AME), consensus 63c... Garmin (GRMN), consensus 57c... Quintiles Transnational (Q), consensus 71c... New York Community Bancorp (NYCB), consensus 26c... Spirit Aerosystems (SPR), consensus 92c... Spirit Airlines (SAVE), consensus 96c... Brunswick (BC), consensus 61c... KBR (KBR), consensus 17c... Linn Energy (LINE), consensus (20c)... Cullen/Frost Bankers (CFR), consensus $1.09... WEX (WEX), consensus 99c... RPC (RES), consensus 11c... Hercules Offshore (HERO), consensus (38c).
05:53 EDTCELGStocks with implied volatility movement; AMGN CELG
Subscribe for More Information
April 27, 2015
09:21 EDTDELLDell to resell Aerohive’s solutions worldwide
Aerohive Networks announced that Dell will resell Aerohive’s solutions worldwide, offering Dell’s customers the combination of Aerohive’s Wi-Fi and cloud services, and Dell’s set of solutions from the data center all the way to endpoint devices. Under the agreement and relationship announced Dell is reselling Aerohive’s award-winning cloud-managed Wi-Fi solutions alongside other Dell products
07:31 EDTCELGCelgene to acquire Quanticel Pharmaceuticals for $100M in cash
Subscribe for More Information
07:13 EDTDELLUBM Tech to hold a conference
Subscribe for More Information
April 26, 2015
12:50 EDTCELGApple, Celgene, others are 'top picks' for spring, Barron's says
In a survey of U.S. money managers, shares of Apple (AAPL), Dow Chemical (DOW), American Airlines (AAL), Celgene (CELG), General Motors (GM), and McDermott (MDR) were identified as top picks for this spring, Barron's contends in its cover story. Reference Link
April 24, 2015
10:59 EDTCELGCelgene call activity attributed to vague takeover speculation
Subscribe for More Information
10:22 EDTCELGRumor: Celgene active on vague takeover speculation
Celgene (CELG) shares are active on speculation Bristol-Myers (BMY) may be interested in acquiring the company.
05:39 EDTCELGCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
April 23, 2015
17:45 EDTCELGCelgene announces fulfillment of approval requirements for POMALYST
Subscribe for More Information
09:20 EDTCELGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1–10 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The ’501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 22, 2015
05:58 EDTGMCRStocks with implied volatility above IV index mean; MNKD GMCR
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use